Novartis cuts CCO title as international chief Marie-France
Just as Novartis’ C-suite appeared to have stabilized amid a major overhaul of the company, the Swiss pharma is losing its international markets leader and getting rid of its chief commercial offic | Just as Novartis’ C-suite appeared to have stabilized amid a major overhaul of the company, the Swiss pharma is losing its international markets leader and getting rid of its chief commercial officer title.
Novartis: Novartis names new board member after international boss steps down - The Economic Times
Ophthalmic Drugs : Pharmaceuticals : UK
Michael Meegan on LinkedIn: Novartis cuts top commercial title
SEC Filing ID 0001438533-24-000005
Brain Tumour Magazine: World Edition 2021/2022 by The
Novartis to cut up to 8,000 jobs globally
Novartis names new board member after international boss steps
European Psychologist by Hogrefe - Issuu
Novartis names new board member after international boss steps
Vas Narasimhan on LinkedIn: Of all the achievements Novartis
RCSI Alumni Magazine 2021 by RCSI - Issuu
Novartis loses commercial chief as Tschudin heads for exit
Frontiers Cell and gene therapy regulatory, pricing, and reimbursement framework: With a focus on South Korea and the EU
In major shake-up, Novartis combines pharma and oncology units